Quanterix Corporation announced on July 8, 2025, that it has completed its previously announced acquisition of Akoya Biosciences, Inc. This transaction establishes a scaled leader in the early detection of disease for the neurology, oncology, and immunology markets.
Under the terms of the amended merger agreement, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards. This marks the culmination of a strategic process that began with the initial merger announcement.
The completion of the acquisition signifies the integration of Akoya's spatial biology platforms with Quanterix's ultra-sensitive biomarker detection technology. This strategic move aims to create the first integrated platform capable of measuring biomarkers across the blood and tissue continuum, impacting future research and clinical applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.